News

The 12-month option provides an additional $2.1 million to Soligenix to advance OrbeShield™ as a medical countermeasure (MCM) for the treatment of gastrointestinal acute radiation syndrome (GI ARS).

Sendai virus enables delivery of genes into a host cell without permanently altering the cell’s chromosome, which is critical for stem cell therapies. Professor Shinya Yamanaka, MD, Ph.D.,

As part of the deal, R-Tech Ueno will receive $54m in cash and 2.5 million Sucampo shares and Sucampo will buy 56% of the outstanding shares of R-Tech

The new R&D centre is part of the company’s global expansion plans to invest BRL20m ($5.6m) in equipment, facilities and technical staff. Initially, 20 specialized professionals will work

The proprietary synthetic molecules called Antibody Recruiting Molecules (ARMs) are developed by professor David Spiegel and his team at Yale University. The ARMs work by harnessing the power

Portage holds 54% equity interest in Biohaven, which filed an investigational drug application (IND) regarding BHV-0223 and recently secured approval from the US Food and Drug Administration (FDA)

Tarloxotinib is the company’s hypoxia-activated, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor licensed from the University of Auckland, New Zealand. The company noted that elevated expression

Earlier, the FDA has approved Jardiance (empagliflozin) and Glyxambi (empagliflozin/linagliptin), while Synjardy is the third product containing empagliflozin that received approval from the agency. Both empagliflozin and metformin

The company paid $232 per share in cash for Receptos, which is focused on developing therapeutic candidates to treat immune and metabolic diseases. The acquisition of Receptos builds